Loading...
R&D Rational 2018-05-28T19:26:09+00:00

THE NEED BEHIND

Inflammatory diseases are clearly lacking a tool to determine the potency (efficacy) of immunosuppressant drugs over the immune cells of the patients, to identify those immunosuppressants that may be more efficacious for each patient at a certain point of time.

Precision Medicine is the current major trend to maximize the opportunity in chronic conditions of saving lives and improving quality of life. This means human diversity responses must be considered. Different patients need different drugs, and this is the driver of new medical management.

Chronic inflammation remains treated with immunosuppressant drugs mostly based on clinical guidelines, drug blood levels and trial/error approaches.

For example, out of the 2 million of patients with renal transplant 60% of those with deficient clinical evolution show a clear resistance to the drug they take (according to our data from BH Pilot study). Moreover, 50% of transplanted organs are lost in 10 years due to rejection. Also 30% of patients with Rheumatoid Arthritis (> 20 millions) have a bad clinical evolution, ending with different types of disabilities.

Inflammatory diseases are clearly lacking a tool to determine the potency (efficacy) of immunosuppressant drugs over the immune cells of the patients, to identify those inmunosuppressants that may be more efficacious for each patient at a certain point of time.

SCIENTIFIC APPROACH TO THE PROBLEM

At Biohope we decided to design a “final point” immunoassay, in terms of a functional or pharmacodynamics assay.

The immune system is very complex, dynamic and self-learning leading to different immunological outcomes that vary day by day, although coming from similar genes. Because of this, genomics itself is not an approach capable of anticipating the full immunological risk profile of a patient at a certain point of time, nor the specific response to drugs.

At Biohope we decided to design a “final point” immunoassay, in terms of a functional or pharmacodynamics assay.

Our value proposition comes from: 1) we use a physiological stimulus for immune cells, 2) we do not separate specific subpopulations for testing because immunosuppressant drugs interact with a system not a cell, rather we keep the system as wide as it is, 3) we let the system time enough to launch fully-conformed responses to analyze how it reacts when confronted with each immunosuppressant drug.

INMUNOBIOGRAM®

BIOHOPE is developing a blood-based Precision Medicine test for chronic inflammatory conditions. It offers a personalized comparative evaluation of patient sensitivity to a panel of immunosuppressant drugs most commonly used. This functional pharmacodynamic and monitoring kit is named Immunobiogram® (IMBG).

This tool will allow the physician to personalize the immunosuppressant therapy, selecting the most adequate medications and doses.
Only a conventional 10mL blood sample from the patient is needed to run the immunoassay.

Data is analyzed with a software and output is an evaluation of the sensitivity degree of patient´s circulating immune cells to a panel of immunosuppressant most recommended in clinical guidelines and most used. The bioassay uses well known immunosuppressants but it can be adapted for testing new compounds against marketed ones.

IMBG allows for a direct comparison between several immunosuppressant drugs in terms of immunosuppressive potency for each specific patient at the time the immunoassay is run.

As the immunological system is very dynamic and can be affected by many factors, it is anticipated that Inmunobiogram® would be better used as a test to monitor patient´s intrinsic response to immunosuppressant drugs over time.

Click here to see the full R & D document